10-K: Tivic Health Systems Reports 2023 Annual Results, Focuses on Bioelectronic Medicine Growth

Tivic Health Systems' 2023 annual report highlights a year of strategic investments in product development and distribution, alongside financial challenges and a focus on bioelectronic medicine.

Summary

• Tivic Health Systems, a bioelectronic medicine company, released its 2023 annual report, detailing its financial performance and strategic initiatives.
• The company experienced a decrease in revenue by 36% to $1.2 million in 2023, compared to $1.8 million in 2022, primarily due to a 52% decrease in unit sales.
• Despite the revenue decline, Tivic improved its gross profit margin by optimizing its supply chain and implementing a price increase.
• The company incurred a net loss of $8.2 million in 2023, compared to a net loss of $10.1 million in 2022.
• Operating expenses decreased by $1.8 million, primarily due to reduced advertising and agency costs, as well as a decrease in legal and professional fees.
• Tivic raised approximately $8.5 million through registered public offerings of common stock during 2023.
• The company is focusing on expanding its bioelectronic medicine platform, including vagus nerve stimulation, and has initiated clinical research programs.
• Tivic has identified several addressable markets for its ClearUP product, including individuals with severe sinus conditions, allergy sufferers, high-performance athletes, and those with sleep apnea.
• The company is also exploring new product candidates for post-operative pain and migraine headaches, though clinical studies for migraine have been deprioritized due to competition.
• Tivic is working to improve its supply chain and reduce manufacturing costs, including a redesign of its ClearUP device to address charging issues.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments in product development and market expansion, the significant revenue decline, net loss, and going concern uncertainty weigh heavily on the overall sentiment. The company's need for additional capital and the competitive landscape also contribute to a cautious outlook.

Positives

• Tivic improved its gross profit margin by optimizing its supply chain and implementing a price increase.
• The company reduced its operating expenses by $1.8 million, primarily due to decreased advertising and legal fees.
• Tivic successfully raised $8.5 million through registered public offerings, providing capital for operations.
• The company is actively expanding its intellectual property portfolio, including a patent in vagus nerve stimulation.
• Tivic has established research collaborations with The Feinstein Institutes for Medical Research to further characterize the effects of its vagus nerve stimulation technology.
• The company has secured distribution agreements with major healthcare distributors, expanding its market reach.
• Tivic has completed a redesign of its ClearUP device to address charging issues and improve usability.
• The company has received recertification to ISO 13485, the international standard for medical device quality systems.

Negatives

• Tivic experienced a significant decrease in revenue by 36% to $1.2 million in 2023, primarily due to a 52% decrease in unit sales.
• The company incurred a net loss of $8.2 million in 2023, indicating ongoing financial challenges.
• Direct-to-consumer product revenue decreased by 34% due to decreased unit sales, despite a price increase.
• Reseller channel product revenue decreased by 37% due to decreased unit sales.
• The company has identified a material weakness in its internal control over financial reporting.
• Tivic's cash and financial resources may be insufficient to meet its anticipated needs for the next twelve months, raising substantial doubt about its ability to continue as a going concern.
• The company has down-prioritized clinical studies of migraine-related indications due to aggressive competition.

Risks

• Tivic has a limited operating history and may not be able to execute its business strategy effectively.
• The company's cash and financial resources may be insufficient to meet its anticipated needs for the next twelve months, raising substantial doubt about its ability to continue as a going concern.
• Tivic's operating results may be volatile and may not be a reliable indicator of future performance.
• The company relies on third parties for supply and manufacturing, which could cause supply shortages.
• Tivic is subject to risks relating to foreign laws and regulations, particularly in China, where it sources electronic components.
• The company is highly dependent on its intellectual property, and its methods of protecting it may not be adequate.
• Tivic's stock price has fluctuated significantly and may continue to do so.
• The company is an emerging growth company and a smaller reporting company, which may make its stock less attractive to investors.
• If Tivic is unable to implement and maintain effective internal control over financial reporting, investors may lose confidence in the accuracy of its financial reports.
• The company is subject to consumer protection laws that regulate its marketing practices and prohibit unfair or deceptive acts or practices.

Future Outlook

Tivic expects to incur substantial additional operating losses for the foreseeable future to expand its markets, complete development of new products, obtain regulatory approvals, launch and commercialize its products, and continue research and development programs. The company anticipates needing additional capital to fund its operations and strategic plans.

Management Comments

• Management expects to incur substantial additional operating losses for the foreseeable future to expand our markets, complete development of new products, obtain regulatory approvals, launch and commercialize our products and continue research and development programs.
• Management expects that our revenues may be volatile as we develop new technology and obtain new customers in the future.
• Management believes its cash and financial resources may be insufficient to meet the Companys anticipated needs for the twelve months following the date of issuance of the financial statements for the year ended December 31, 2023.

Industry Context

Tivic operates in the growing bioelectronic medicine market, which is a branch of the neuromodulation industry. The company's focus on non-invasive treatments aligns with a trend towards less invasive medical interventions. The market for over-the-counter allergy, cough, cold, and flu treatments is projected to be an $11.1 billion market by 2025 in the U.S. alone, indicating a significant opportunity for Tivic's ClearUP product.

Comparison to Industry Standards

• Tivic's ClearUP device is a novel product in the non-drug category, an emerging bioelectronic medicine segment, and currently has a small market share compared to existing pharmaceutical options.
• The company's clinical trial results for ClearUP show a 29.6% reduction in sinus pain and a 35% reduction in congestion, which is comparable to or better than some pharmaceutical treatments.
• Tivic's focus on non-invasive bioelectronic medicine differentiates it from companies developing implantable devices or pharmaceutical treatments.
• The company's approach to vagus nerve stimulation is aimed at improving precision and efficacy compared to existing devices.
• Tivic's research and development efforts are focused on expanding the applications of its technology to other clinical conditions, such as post-operative pain and migraine headaches, which are areas with significant unmet needs.
• The company's reliance on third-party manufacturers and suppliers is common in the medical device industry, but it also exposes Tivic to supply chain risks.
• Tivic's financial performance is not yet comparable to established pharmaceutical companies, but its focus on innovation and emerging markets positions it for potential growth.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings.

Related Party Transactions

• The Company incurred $14 thousand and $18 thousand of expenses in 2023 and 2022, respectively, for product development consultation services with a significant shareholder.

Stakeholder Impact

• Shareholders may experience dilution due to future issuances of stock.
• Employees may be affected by potential cost-cutting measures and changes in management.
• Customers may benefit from new product developments and expanded distribution channels.
• Suppliers may be impacted by changes in the company's supply chain strategy.
• Creditors may be concerned about the company's ability to continue as a going concern.

Next Steps

• Tivic plans to increase its research and development investments in its vagus nerve platform and clinical applications thereof in 2024.
• The company will continue to evaluate alternative and secondary source suppliers to ensure sufficient component sourcing.
• Tivic will continue to monitor the global economic situation and its potential impact on the company's operations.
• The company will continue to evaluate potential strategic acquisitions that align with its growth plan.

Key Dates

Keywords

bioelectronic medicine, neuromodulation, ClearUP, sinus pain, congestion, vagus nerve stimulation, medical device, FDA, CE Mark, clinical trials, supply chain, intellectual property, market segmentation, distribution agreements, financial results